Impact of Fecal Biotherapy (FBT) on Microbial Diversity in Patients With Moderate to Severe Inflammatory Bowel Disease

Exclusion Criteria

• •Diagnosis of indeterminate colitis, or proctitis alone
• •Severe or fulminate colitis
• •Women who are pregnant or nursing
• •Patients who are unable to give informed consent
• •Patients who are unable or unwilling to undergo colonoscopy with moderate sedation (\>ASA class II)
• •Patients who have previously undergone FMT
• •Patients who have a confirmed malignancy or cancer
• •Patients who are immunocompromised
• •Treatment within last 12 weeks with cyclosporine, tacrolimus, infliximab, adalimumab, certolizumab, natalizumab, thalidomide
• •Antibiotic use within 2-months of start date
• •Participation in a clinical trial in the preceding 30 days or simultaneously during this trial
• •Probiotic use within 30 days of start date
• •Rectal therapy within 14 days of start date
• •Decompensated cirrhosis
• •Congenital or acquired immunodeficiencies
• •Other comorbidities including:
• •Diabetes mellitus, cancer, systemic lupus, must be able to tolerate conscious sedation with colonoscopy
• •Chronic kidney disease as defined by a GFR \<60mL/min/1.73m2 44
• •History of rheumatic heart disease, endocarditis, or valvular disease due to risk of bacteremia from colonoscopy
• •Steroid dose \>20mg/day